Understanding how tumor-specific MUC1 glycopeptides interact with immune cells
Mechanistic insight into tumor-associated MUC1 glycopeptides binding to macrophage galactose-type lectin
['FUNDING_R15'] · FLORIDA ATLANTIC UNIVERSITY · NIH-10806443
This study is looking at how certain parts of a protein that change in cancer can connect with immune cells, helping us understand how tumors avoid being attacked by the immune system, and it could lead to better ways to boost cancer treatments.
Quick facts
| Phase | ['FUNDING_R15'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FLORIDA ATLANTIC UNIVERSITY (nih funded) |
| Locations | 1 site (BOCA RATON, UNITED STATES) |
| Trial ID | NIH-10806443 on ClinicalTrials.gov |
What this research studies
This research investigates how specific glycopeptides from the MUC1 protein, which are altered in cancer, bind to immune cells. By examining these interactions, the study aims to uncover how tumors evade the immune system and promote their own growth. The researchers will create synthetic versions of these glycopeptides to better understand their binding properties and effects on immune responses. This could lead to new strategies for enhancing cancer immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with epithelial cancers that express altered MUC1 glycopeptides.
Not a fit: Patients with non-epithelial cancers or those whose tumors do not express MUC1 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments by enhancing the immune system's ability to recognize and attack tumors.
How similar studies have performed: Previous research has shown promise in targeting glycopeptides for cancer immunotherapy, suggesting that this approach could be effective.
Where this research is happening
BOCA RATON, UNITED STATES
- FLORIDA ATLANTIC UNIVERSITY — BOCA RATON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CUDIC, MARE — FLORIDA ATLANTIC UNIVERSITY
- Study coordinator: CUDIC, MARE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer-Associated Carbohydrate Antigens